Quarter Period Consolidated Statement Of Income

OncoTherapy Science, Inc. - Filing #7595079

Concept 2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
Quarter period consolidated statement of income
Statement of income
Net sales
385,703,000 JPY
5,665,000 JPY
-55,000 JPY
380,093,000 JPY
385,759,000 JPY
101,579,000 JPY
-8,395,000 JPY
5,938,000 JPY
95,640,000 JPY
93,183,000 JPY
Cost of sales
339,261,000 JPY
76,686,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
120,202,000 JPY
120,170,000 JPY
Operating profit (loss)
-307,352,000 JPY
-215,473,000 JPY
-101,150,000 JPY
9,271,000 JPY
-206,202,000 JPY
-464,449,000 JPY
-107,068,000 JPY
-431,256,000 JPY
-33,193,000 JPY
-571,517,000 JPY
Non-operating income
Interest income
JPY
63,000 JPY
Non-operating income
JPY
452,000 JPY
Non-operating expenses
Non-operating expenses
6,740,000 JPY
444,000 JPY
Ordinary profit (loss)
-314,093,000 JPY
-571,509,000 JPY
Extraordinary income
Gain on sale of non-current assets
JPY
49,000 JPY
Extraordinary income
37,755,000 JPY
47,902,000 JPY
Extraordinary losses
Impairment losses
751,000 JPY
11,036,000 JPY
Extraordinary losses
751,000 JPY
11,036,000 JPY
Profit (loss) before income taxes
-277,089,000 JPY
-534,644,000 JPY
Income taxes - current
724,000 JPY
724,000 JPY
Income taxes - deferred
-14,000 JPY
-439,000 JPY
Income taxes
710,000 JPY
284,000 JPY
Profit (loss)
-277,799,000 JPY
-534,929,000 JPY
Profit attributable to
Profit (loss) attributable to owners of parent
-277,799,000 JPY
-534,929,000 JPY
Comprehensive income
-277,799,000 JPY
-534,929,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
-277,799,000 JPY
-534,929,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.